MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 584
- Registration Number
- NCT02054130
- Locations
- 🇺🇦
Research Site, Zaporizhzhya, Ukraine
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 68
- Registration Number
- NCT02027961
- Locations
- 🇮🇹
Research Site, Napoli, Italy
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 58
- Registration Number
- NCT02013804
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1
Completed
- Conditions
- NSCLCNon-small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 459
- Registration Number
- NCT02000947
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
Terminated
- Conditions
- Influenza Vaccine Effectiveness
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 4121
- Registration Number
- NCT01997450
- Locations
- 🇬🇧
Research Site, Tooting, United Kingdom
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
Completed
- Conditions
- Observation Safety
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 95000
- Registration Number
- NCT01985997
- Locations
- 🇺🇸
Research Site, Oakland, California, United States
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: AMP-110Other: Placebo
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01878123
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Metroplex Clinical Research Center, Dallas, Texas, United States
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
Phase 4
Completed
- Conditions
- HealthyInfluenza
- Interventions
- Other: PlaceboBiological: Trivalent Influenza Vaccine
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 300
- Registration Number
- NCT01859143
- Locations
- 🇺🇸
Research Site, Portland, Oregon, United States
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
Phase 2
Active, not recruiting
- Conditions
- Unresectable Pleural or Peritoneal Malignant Mesothelioma
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 571
- Registration Number
- NCT01843374
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Phase 3
Completed
- Conditions
- Leukemia, Hairy Cell
- Interventions
- Drug: IV Bag Protectant for Moxetumomab pasudotox
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01829711
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath